Evidence map›Paper›PMID 33997811›Full record

ArticleSTAR protocols2021

Measurement of labile and protein-bound heme in fixed prostate cancer cells and in cellular fractions.

Giacomo Canesin, Lubica Janovicova, Barbara Wegiel

Open access · goldAbstract read
In one paragraph

Article in STAR protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Giacomo CanesinDepartment of Surgery, Division of Surgical Oncology, Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02214, USA.
Lubica JanovicovaDepartment of Surgery, Division of Surgical Oncology, Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02214, USA.
Barbara WegielDepartment of Surgery, Division of Surgical Oncology, Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02214, USA.
Beth Israel Deaconess Medical Center · US

Funding

Characterizing the role of the heme catabolism in tissue damage and inflammation.R01DK125846 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEGIEL, BARBARA · 2021 to 2024
$2.1M
Role of biliverdin reductase during sterile inflammation in the liver.R01DK104714 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEGIEL, BARBARA · 2016 to 2020
$2.0M
Determining the role of gas metabolite in response to immunotherapyR21CA256720 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEGIEL, BARBARA · 2021 to 2022
$445k
Heme degradation pathway and immunomodulation in prostate cancer.R21CA169904 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEGIEL, BARBARA · 2013 to 2014
$411k
NCI NIH HHS R21 CA169904NCI NIH HHS R21 CA256720NIDDK NIH HHS R01 DK104714NIDDK NIH HHS R01 DK125846
6 · The paper itself

Abstract

Labile heme is present in the cells at very low concentrations, either unbound or loosely bound to molecules, and accessible for signaling as alarmin. Our recent work suggests that extracellular heme can be taken up and detected in the nuclei of cancer cells. Here, we describe the detailed protocol for detection of labile and total heme in prostate cancer cells and its measurement in subcellular compartments

Indexed as

Prostatic NeoplasmsCell Culture TechniquesCell FractionationCell Line, TumorCells, ImmobilizedColorimetryHemeHumansMaleHemeCancerCell-based AssaysCell BiologyCell separation/fractionationProtein Biochemistry

Identifiers

PMID33997811
PMCPMC8091920
OpenAlexW3154323445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.